Literature DB >> 34929063

A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.

Matthew S Davids1, Mazyar Shadman2,3, Sameer A Parikh4, Chaitra Ujjani3, Jennifer L Crombie1, Dingfeng Jiang5, Cynthia Llamas5, Dai Feng5, Nicole Lamanna6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34929063     DOI： 10.1002/ajh.26444

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  1 in total

1.  Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

Authors:  Xin Victoria Wang; Curtis A Hanson; Renee C Tschumper; Connie E Lesnick; Esteban Braggio; Elisabeth M Paietta; Susan O'Brien; Jacqueline C Barrientos; Jose Francisco Leis; Cong Christine Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Harry Erba; Richard Stone; Mark R Litzow; Martin S Tallman; Tait D Shanafelt; Neil E Kay
Journal:  Blood       Date:  2021-12-30       Impact factor: 25.476
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.